Lung neoplasm

This study tests a combination of drugs (berzosertib, carboplatin, gemcitabine, and pembrolizumab) in people with advanced squamous non-small cell lung cancer that has spread. The goal is to find the best dose and see if the combo helps control the cancer longer than standard tre…

This phase III trial is testing two different treatment sequences for people with advanced non-squamous non-small cell lung cancer. One group starts with the immunotherapy drug pembrolizumab alone, then adds chemotherapy only if the cancer progresses. The other group receives pem…

This study is for people with non-small cell lung cancer who have had chemotherapy and surgery. It tests whether adding a drug called AZD6738 to the immunotherapy drug durvalumab can help keep the cancer from coming back longer than durvalumab alone. About 630 adults with stage I…

This early-phase trial is testing whether combining two drugs—vismodegib and atezolizumab—is safe and tolerable for people with advanced non-small cell lung cancer that has returned or spread. Vismodegib blocks certain enzymes that help cancer cells grow, while atezolizumab helps…

This study tests whether adding local treatments like surgery or radiation to a combination of two immunotherapy drugs (nivolumab and ipilimumab) helps people with stage IV non-small cell lung cancer live longer compared to immunotherapy alone. About 339 participants who have not…

This study looks at whether adding surgery or radiation to the targeted drug osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their cancer growing. About 173 participants will receive either osimertinib alone or osimertinib plus lo…

This phase 3 trial compares a new drug, divarasib, to two existing targeted therapies (sotorasib and adagrasib) in 338 people with advanced or metastatic non-small cell lung cancer that has a specific KRAS G12C mutation and has progressed after prior treatment. Participants take …

This study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…

This study tests the safety and best dose of adding telaglenastat to the standard drug osimertinib for people with stage IV non-small cell lung cancer that has a specific EGFR mutation. The two drugs work together to block enzymes that cancer cells need to grow. The trial involve…

This phase II trial tests a new approach for advanced non-small cell lung cancer that hasn't responded to standard treatments. It combines photoimmunotherapy (ASP-1929), a light-activated drug that targets cancer cells, with cemiplimab, an immunotherapy that boosts the immune sys…

This Phase III trial tests whether giving radiation in three smaller doses (FSRS) works better than a single large dose (SRS) for cancer that has spread to the brain. About 269 adults with lung, breast, melanoma, kidney, or gastrointestinal cancers will be randomly assigned to on…

This early-stage trial tests the safety of combining precise radiation (SBRT) with immunotherapy (durvalumab) and two chemotherapy drugs (platinum and etoposide) for people with extensive-stage small cell lung cancer that has stopped responding to platinum chemo. The study aims t…

This phase III trial is testing whether a precise, high-dose radiation technique called stereotactic radiosurgery (SRS) is better at preserving memory and thinking than the current standard of whole brain radiation that avoids the hippocampus (the brain's memory center) plus a dr…

This study looks at whether using focused radiation (stereotactic radiosurgery) only on the brain tumors, instead of the whole brain, can help preserve thinking and memory in people with small cell lung cancer that has spread to the brain. About 55 participants will receive this …

This early-phase trial tests whether combining two immunotherapy drugs (ipilimumab and nivolumab) with radiation therapy is safe and effective for patients with stage II or III non-small cell lung cancer that cannot be surgically removed. The study enrolls 21 participants who hav…

This early-stage trial tests a new type of immunotherapy called CD70-targeted CAR-T cells in people with advanced solid tumors, including kidney, lung, ovarian, and thyroid cancers. The treatment involves taking a patient's own immune cells, engineering them to recognize and atta…

This early-phase trial is testing an experimental drug called TTX-080, which blocks a protein (HLA-G) that tumors use to hide from the immune system. The study will give TTX-080 alone or combined with other cancer drugs (pembrolizumab, cetuximab, or FOLFIRI plus cetuximab) to abo…

This study tests two new treatments—cabozantinib alone or with nivolumab—against standard chemotherapy for people with advanced non-squamous lung cancer that has returned. The goal is to see if these combinations can slow cancer growth better than current options. About 117 adult…

This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…

This phase 2 trial tests a combination of three drugs—tiragolumab, atezolizumab, and bevacizumab—in people with advanced non-squamous non-small cell lung cancer that has already been treated. The goal is to see if the combination can shrink tumors or slow disease progression. Abo…

This phase II trial tests whether adding two types of precisely targeted radiation (BgRT and SBRT) to the standard drug osimertinib can better control advanced EGFR-positive lung cancer that has started to grow in a few new spots. About 32 adults with this specific type of lung c…

This study tests a new drug called JDQ443 in people with advanced lung cancer that has a specific genetic change (KRAS G12C mutation) and does not respond well to standard treatments. The drug is taken as a pill and aims to shrink or control the cancer. About 95 participants will…

This early-stage trial is testing a new drug called tarlatamab, which helps the immune system find and attack cancer cells, when given together with standard chemotherapy and immunotherapy. The study includes about 184 people with extensive-stage small cell lung cancer who have n…

This Phase 3 trial tests whether a combination of two immunotherapy drugs (acasunlimab and pembrolizumab) works better than the standard chemotherapy docetaxel for people with a specific type of advanced lung cancer (PD-L1 positive NSCLC) that has worsened after prior treatment. …

This phase 2 trial tests a combination of two drugs—ceralasertib (a pill) and durvalumab (an infusion)—in 39 adults with advanced or metastatic non-small cell lung cancer that has worsened after standard treatments like immunotherapy and chemotherapy. The main goal is to see if t…

This phase III trial studies whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can help people with stage 3 non-small cell lung cancer that cannot be surgically removed. About 660 participants will receive either chemoradiation plus durvaluma…

This early-phase study tests the safety and best dose of a drug called veliparib when given with two chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors that have spread or can't be removed. It includes patients who also have liver or kidney probl…

This study tests whether adding the experimental drug TRC102 to standard treatment (chemotherapy, radiation, and immunotherapy) can help shrink tumors and extend survival in people with stage III non-squamous lung cancer. TRC102 blocks cancer cells from repairing damage, making t…

This study tests whether combining two drugs, savolitinib and durvalumab, can help control advanced lung cancer in people whose tumors have a specific genetic change called MET alteration. About 47 adults in China with non-small cell lung cancer that has spread will receive the c…

This early trial tests a radioactive drug called MNPR-101-PCTA-177Lu in adults with advanced solid tumors, including bladder, breast, lung, and pancreatic cancers. Participants receive three equal doses by IV over two 12-week cycles. The main goal is to find a safe dose and under…

This phase III trial is testing whether giving chemotherapy and immunotherapy both before and after surgery (perioperative) is better than giving it only after surgery (adjuvant) for people with stage II-IIIB non-small cell lung cancer that can be removed. About 1,100 participant…

This study tests whether combining two drugs, atezolizumab and cobimetinib, can help people with advanced non-small cell lung cancer whose tumors stopped responding to standard immunotherapy. About 51 adults with metastatic or recurrent lung cancer will receive the combination. T…

This phase 2 trial is testing a combination of two immunotherapy drugs, zimberelimab and domvanalimab, as a first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. The study includes 169 participants and aims to see if t…

This phase 2 trial tests a combination of two drugs, olomorasib and pembrolizumab, as a first treatment for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and a PD-L1 score between 1% and 49%. The main goal is to see how long patients live without t…

This early-phase trial tests a radioactive drug called tin-117m-DTPA in 24 people with prostate, breast, or lung cancer that has spread to the bones. The drug is designed to deliver low-level radiation directly to bone tumors while being gentler on the bone marrow. Researchers wi…

This Phase 3 trial compares a new oral drug, JDQ443, to the standard chemotherapy docetaxel in about 95 people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. Participants have already tried platinum-based chemo and an immunotherapy drug. The stud…

This phase III trial studies whether adding the immunotherapy drug atezolizumab to standard chemoradiation helps people with limited stage small cell lung cancer live longer. About 544 participants receive either chemoradiation alone or chemoradiation plus atezolizumab. The main …

This phase 3 trial tests whether adding the targeted drug zipalertinib to standard chemotherapy can delay or prevent lung cancer from returning in people with early-stage non-small cell lung cancer (stages IB to IIIA) who have uncommon EGFR mutations. After complete tumor removal…

This early-stage trial tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. It is a firs…

This phase II trial tests a shorter, higher-dose radiation therapy followed by the immunotherapy drug atezolizumab in 47 patients with stage II or III non-small cell lung cancer who have borderline health. The goal is to see if this approach is safe and effective for people who c…

This study tests whether adding a third drug to standard immunotherapy (cemiplimab) plus chemotherapy works better for people with early-stage non-small cell lung cancer who can have surgery. About 120 adults will receive treatment before and after their operation. The main goal …

This Phase 3 trial tests whether the oral drug zongertinib can slow cancer growth better than standard chemotherapy plus immunotherapy in people with advanced HER2-mutant non-small cell lung cancer. About 428 adults who have not had prior treatment for advanced disease will be ra…

This early-phase trial is testing whether the immunotherapy drug nivolumab can help people with melanoma or lung cancer that has spread to the leptomeninges (the lining of the brain and spinal cord). The drug is given both through a vein and directly into the spinal fluid via a l…

This study tests whether giving the targeted drug osimertinib before and after standard chemoradiation helps control stage III lung cancer that cannot be removed by surgery. About 76 adults with a specific EGFR gene mutation will receive the drug as induction therapy, then contin…

This early-phase trial tests whether adding NBTXR3 nanoparticles to radiation therapy can safely treat inoperable non-small cell lung cancer that has come back after prior radiation. The nanoparticles are designed to concentrate radiation energy inside tumor cells, potentially ki…

This study is for people with advanced non-small cell lung cancer that does not have the PD-L1 marker, making it harder to treat with immunotherapy alone. The trial compares standard immunotherapy (with or without chemotherapy) to the same treatment plus radiation therapy. The go…

This study looks at how well the drug osimertinib combined with chemotherapy works as the first treatment for people with advanced EGFR-mutant non-small cell lung cancer. It involves 532 adults with stage IIIB, IIIC, or IV disease who cannot have surgery or radiation. Researchers…

This study tests a procedure called cryodevitalization, which uses a flexible probe to freeze and kill early-stage lung cancer cells. It is done during a standard biopsy. The goal is to find the safest freezing time and see if the treatment is tolerable for 30 patients with stage…

This study offers continued access to the cancer drug ruxolitinib (sometimes combined with other therapies) for people with pancreatic, colorectal, breast, or lung cancer who were already benefiting and stable in a prior Incyte-sponsored trial. Only 10 participants are enrolled, …

This phase 2 study compares two dosing schedules of the targeted drug adagrasib (Krazati) in 200 adults with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. Participants have already tried chemotherapy and immunotherapy. The goal is to see if a lower d…

This phase II trial tested whether adding bevacizumab to osimertinib works better than osimertinib alone for patients with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the brain. Only 5 patients were enrolled. The goal was to see if t…

This phase 2 trial tests whether adding petosemtamab to the standard immunotherapy pembrolizumab can shrink tumors in adults with metastatic non-small cell lung cancer. About 180 participants will receive the combination as their first treatment. The study focuses on how many pat…

This early-phase trial is testing a combination of four drugs—ensartinib, two chemotherapy drugs, and a targeted antibody—in 12 people with advanced ALK-positive non-small cell lung cancer. The goal is to find the safest dose and see how well the combination controls the disease.…

This trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…

This study combines the CIMAvax EGF vaccine with immunotherapy drugs (nivolumab or pembrolizumab) to treat advanced non-small cell lung cancer and squamous head and neck cancer. The vaccine aims to slow tumor growth, while the immunotherapy helps the immune system attack cancer c…

This early-phase study tests whether a new treatment called KSQ-001EX is safe for people with advanced solid tumors like melanoma, lung cancer, or head and neck cancer. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are genetically modified …

This early-phase trial tests a drug called WSD0922-FU in 56 people with certain brain cancers (glioblastoma, anaplastic astrocytoma) or lung cancer that has spread to the brain or spinal cord. The drug blocks a protein called EGFR that helps cancers grow, and is designed to reach…

This trial tests whether starting to eat and move soon after lung cancer surgery (lobectomy) can improve recovery. Half of the participants will follow an enhanced recovery protocol, sitting up and walking within hours of surgery and starting liquids early, while the other half r…

This phase 2 study tests whether combining the immunotherapy drug durvalumab with radiation therapy (without chemotherapy) can delay cancer worsening in people with locally advanced non-small cell lung cancer. About 61 participants will receive radiation plus durvalumab infusions…

This early-stage trial is testing whether combining three drugs—pembrolizumab, guadecitabine, and mocetinostat—can safely treat advanced non-small cell lung cancer (NSCLC) in people whose cancer has progressed after prior immunotherapy. The study aims to find the safest doses of …

This study tests whether a simple blood test that measures cancer DNA (ctDNA) can help doctors decide when to add chemotherapy to the standard immunotherapy drug pembrolizumab for people with advanced lung cancer. About 230 participants will be enrolled. The goal is to see if thi…

This early-phase trial tests a new drug called M6620 (berzosertib) combined with the chemotherapy irinotecan in people with advanced solid tumors that have spread or can't be removed. The goal is to find the safest dose and see if the combination can slow tumor growth. About 66 p…

This early-phase trial studies the safety and best dose of adding necitumumab to osimertinib for people with advanced EGFR-mutant non-small cell lung cancer that has worsened after previous treatment. About 138 participants will receive the combination to see if it is tolerable a…

This early-phase trial tests an experimental drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially urothelial cancer. The goal is to find the best dose and see how safe the combination…

This study tests a combination of three drugs (chemotherapy, anti-angiogenesis, and immunotherapy) in 30 adults with advanced non-small cell lung cancer that worsened after standard treatments. The goal is to see if this triple therapy is safe and works better than current option…

This phase II trial tests a three-step approach for stage II or III non-small cell lung cancer. First, the main tumor gets a high-dose radiation blast (SBRT). Then, the chest lymph nodes receive standard radiation plus chemotherapy. Finally, patients get an immunotherapy drug (du…

This study tests whether adding valemetostat to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has high PD-L1 levels. About 137 adults who have not had prior treatment will participate. The g…

This trial investigates whether real-time motion management techniques—like triggered imaging and MLC tracking—can safely reduce the target margins used during radiotherapy for prostate and lung cancer. By adjusting the radiation beam to follow tumor movement, researchers aim to …

This study tests whether a precise type of radiation called SBRT can restore the effectiveness of immunotherapy drugs in people whose metastatic cancer has started to progress. About 69 adults with melanoma, lung, bladder, kidney, or head/neck cancers will receive radiation to up…

This study tests a new experimental drug, sigvotatug vedotin, against a standard chemotherapy, docetaxel, in people with advanced non-small cell lung cancer that has spread or can't be removed. The goal is to see if the new drug helps people live longer. About 762 adults who have…

This early-stage study tests a new experimental drug called PF-07934040, taken as a pill, for people with advanced solid tumors that have a KRAS gene mutation. The trial includes patients with non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Researchers will …

This study tests an experimental oral drug called silevertinib (BDTX-1535) in about 200 adults with advanced non-small cell lung cancer or glioblastoma, a type of brain cancer. The drug is designed to block specific EGFR mutations that help these cancers grow. The trial has two p…

This study tests a treatment using a patient's own immune cells (T cells) that are genetically modified to recognize and attack a protein called mesothelin found on cancer cells. The treatment is given through a tube in the chest to people with malignant pleural disease, includin…

This study tests whether a shot (subcutaneous injection) of pembrolizumab works as well as the standard IV infusion for people with metastatic non-small cell lung cancer that has high PD-L1 levels. About 67 participants will receive either the shot or IV treatment, and researcher…

This phase 3 trial tests whether adding the immunotherapy drug durvalumab to standard radiation therapy helps prevent early-stage non-small cell lung cancer from progressing. It includes about 724 patients who cannot have surgery. A separate group of patients with a specific EGFR…

This early-stage trial is testing a new oral drug called LY4066434, which blocks several types of KRAS proteins that drive cancer growth. The study includes up to 750 people with advanced pancreatic, lung, colorectal, or other solid tumors that have specific KRAS mutations. The d…

This early-phase trial tests a new treatment for people with advanced non-small cell lung cancer that has stopped responding to standard immunotherapy. The treatment uses immune cells from umbilical cord blood that are genetically modified to better recognize and attack cancer ce…

This study tests whether adding two antibody drugs (trastuzumab and necitumumab) to the standard pill osimertinib can shrink tumors in people with a specific type of advanced lung cancer (EGFR-mutated) that has stopped responding to osimertinib alone. About 30 participants will r…

This study tests whether adding the drug MPDL3280A (a type of immunotherapy) to standard chemotherapy and radiation is safe for people with advanced non-small cell lung cancer that cannot be surgically removed. About 52 participants will receive the combination and be monitored f…

This study tests a combination of two drugs—pembrolizumab (an immunotherapy) and trametinib (a targeted therapy)—in people with advanced non-small cell lung cancer that has come back or spread. The goal is to see if the combination is safe and can shrink or control tumors. Partic…

This study compared two surgical approaches for early-stage lung cancer: removing the entire lobe (lobectomy) versus removing just the tumor with a small margin (sublobar resection). Over 700 patients with small peripheral tumors were randomly assigned to one surgery. The goal wa…

This study tests whether a pulmonary rehabilitation program can improve lung function enough to make lung cancer patients eligible for surgery. Researchers will enroll 75 patients who were initially deemed unable to have surgery due to poor lung health. The goal is to see if reha…

This study tests whether adding fianlimab to standard immunotherapy (cemiplimab) and chemotherapy improves outcomes for people with advanced non-small cell lung cancer. About 950 participants will receive either the triple combination or the double combination. The goal is to see…

This study tests whether using highly focused radiation on each individual brain tumor, instead of radiating the whole brain, can control cancer spread while protecting memory and thinking. It enrolls people with small cell lung cancer who have 1 to 10 brain metastases. Researche…

This study tests whether a new drug combination (ceralasertib plus durvalumab) works better than standard chemotherapy (docetaxel) for people with advanced non-small cell lung cancer that has stopped responding to prior treatments. About 594 participants will be randomly assigned…

This study tests a therapy called CEA CAR-T, which uses a patient's own immune cells modified to recognize and attack cancer cells that carry a protein called CEA. It is for adults aged 18-75 with advanced or recurrent solid tumors (such as lung, colorectal, liver, pancreatic, ga…

This early-phase trial tests the safety of combining three drugs—osimertinib, a platinum chemotherapy (cisplatin or carboplatin), and etoposide—in people with metastatic EGFR mutant lung cancer that also has changes in the RB1 and TP53 genes. The goal is to find the highest safe …

This study tests an experimental drug called TNG260 combined with an immunotherapy (pembrolizumab) in people with advanced solid tumors that have a specific gene change (STK11 mutation). The goal is to find the best dose and see if the combination is safe and can shrink tumors. A…

This early-phase trial tests whether adding bevacizumab to brigatinib can help people with ALK-positive non-small cell lung cancer whose disease has worsened on previous ALK-targeted therapy. The study enrolls just 5 patients and focuses on safety, side effects, and finding the b…

This study is for people with a specific type of lung cancer (non-squamous non-small cell) that has a KRAS G12C mutation and can be removed with surgery. It tests whether giving a targeted drug (sotorasib) plus standard chemotherapy before surgery can shrink the tumor more than c…

This trial aimed to test a new treatment for advanced lung cancer using specially grown immune cells (LC-CTLs) designed to attack cancer. The study was withdrawn before enrolling any participants, so no results are available. It was planned as an early safety and lab-effectivenes…

This phase 2 trial tests whether combining the targeted drug adagrasib with immunotherapy (pembrolizumab) and chemotherapy can shrink tumors or delay progression in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The study enrolls adults wh…

This study tests whether adding an immunotherapy drug (nivolumab) to precise, high-dose radiation therapy helps prevent lung cancer from coming back in people with early-stage non-small cell lung cancer. About 140 participants will receive either radiation alone or radiation plus…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This phase 2 trial tests whether combining sacituzumab govitecan (a targeted antibody-drug conjugate) with pembrolizumab (an immunotherapy) before and after surgery can improve outcomes for people with resectable non-small cell lung cancer (NSCLC). Participants receive four cycle…

This phase 3 trial tests whether adding the immunotherapy drug atezolizumab to standard radiation therapy (SBRT) helps people with early-stage non-small cell lung cancer live longer. About 415 participants with high-risk stage I-IIA lung cancer will receive either SBRT alone or S…

This study tests a combination of the PARP inhibitor olaparib, the immunotherapy durvalumab, chemotherapy (carboplatin and etoposide), and radiation in people with extensive-stage small cell lung cancer who haven't been treated yet. The goal is to see if this mix is safe and work…

This early study tests a new device that uses electric pulses to destroy malignant lung nodules in people with early-stage lung cancer or limited lung metastases. Five participants will undergo a procedure where a needle is guided into the tumor using CT scans, then delivers elec…

This trial is testing a combination of the immunotherapy drug tislelizumab plus two chemotherapy drugs (albumin-bound paclitaxel and a platinum agent) in 30 people with a specific type of lung cancer called KRAS-mutant non-small cell lung cancer. The participants have advanced or…

This phase 2 study tests several new drug combinations in people with non-small-cell lung cancer. It includes three substudies: one for untreated advanced cancer, one for cancer that has progressed after prior treatment, and one for early-stage cancer that can be surgically remov…

This early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.

This early-phase trial is testing two oral drugs, Sapanisertib and Telaglenastat, in 22 people with advanced non-small cell lung cancer that has spread to the brain or other organs. The drugs work by blocking key enzymes that cancer cells need to grow. The main goal is to find th…

This study tests whether using a sensitive blood test (MRD) to guide follow-up treatment can improve outcomes for people with a specific type of advanced lung cancer (EGFR-mutant stage III NSCLC). Participants first receive a targeted pill (aumolertinib), then a team of doctors d…

This study tests a new drug called PLB1004 in people with advanced or spreading non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors and how safe it is. About 139 adults who have already tried oth…

This study tests whether adding an experimental drug (N-803) to the immunotherapy pembrolizumab can help control advanced non-small cell lung cancer better than standard treatments. The drug combo aims to activate natural killer cells and boost the immune system's attack on cance…

This phase 2 trial tests two drugs, durvalumab and oleclumab, given together after standard chemoradiation in 30 people with stage III lung cancer that cannot be removed by surgery. The goal is to see if the combination can delay cancer progression. Participants must have stable …

This early-phase study tests a new drug called RMC-6291 in adults with advanced cancers (lung, colon, pancreatic) that have a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the drug works. About 222 participants will receive the drug by mouth, a…

This study tests whether adding the drugs pembrolizumab and olaparib to standard chemoradiation helps people with stage III non-small cell lung cancer live longer without their cancer growing. About 870 participants will receive one of three treatments: pembrolizumab with chemora…

This early-phase study tests whether combining two cancer drugs—ceritinib and docetaxel—can safely help people with advanced non-small cell lung cancer that has not responded to other treatments. About 21 adults with stage IIIB or IV disease will receive the drugs to find the bes…

This study tests whether adding the drug durvalumab to targeted radiation (SBRT) can help keep early-stage non-small cell lung cancer from coming back. It included 13 people with stage I to IIIA disease. The main goal was to see how long they lived without their cancer getting wo…

This study tests whether combining two targeted drugs, alectinib and cobimetinib, can safely treat advanced ALK-positive non-small cell lung cancer. Researchers will first find the best dose with acceptable side effects, then measure how often tumors shrink. The trial enrolls 16 …

This study tested a new treatment for people with extensive-stage small cell lung cancer, a fast-growing type of lung cancer that has spread. The treatment combined low-dose radiation, an immunotherapy drug (durvalumab), and standard chemotherapy. The goal was to see if this comb…

This phase 2 trial is testing a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus two cycles of chemotherapy as a first treatment for people with advanced lung cancer that has spread to the brain. The study aims to see if this approach can control the cancer …

This study compares two standard treatments for lung tumors: microwave ablation, which uses heat to kill cancer cells, and surgical wedge resection, which removes a small piece of lung. Researchers want to see which method works better and is safer for patients with non-small cel…

This phase 2 study tests a combination of two targeted drugs, encorafenib and binimetinib, in Chinese patients with advanced non-small cell lung cancer that has a specific BRAF V600E mutation. The goal is to see if the drugs can shrink tumors and control the disease. About 63 pat…

This phase II trial is testing whether adding two targeted drugs (pembrolizumab and lenvatinib) to standard chemotherapy can help people with extensive-stage small cell lung cancer live longer without their cancer growing. The study involves 46 participants who have not had prior…

This study aimed to compare three different immunotherapy drug regimens given before and after surgery for people with early-stage non-small-cell lung cancer. The goal was to see which approach best prevented the cancer from coming back. However, the trial was withdrawn before en…

This early-phase trial is testing the safety and best dose of a drug called berzosertib when given together with whole brain radiation therapy. The study includes 15 people with lung cancer that has spread to the brain. The goal is to find out if this combination is safe enough t…

This early-phase trial tests two drugs, tepotinib and pembrolizumab, together in 19 people with advanced non-small cell lung cancer. Tepotinib targets a specific gene change (MET) that can help cancer grow, while pembrolizumab boosts the immune system. The goal is to see if this …

This early-phase study tests a new radioactive drug, 225Ac-ABD147, in people with small cell lung cancer or large cell neuroendocrine lung cancer that has spread and was previously treated with platinum chemotherapy. The main goals are to check safety, find the best dose, and see…

This study tests a new drug called PLB1004 against standard chemotherapy for people with advanced non-small-cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). About 327 adults with this cancer type will be randomly assigned to receive either PLB1004 or …

This study tests two drugs together for people with small cell lung cancer or other high-grade neuroendocrine cancers that have already been treated. Niraparib blocks a DNA repair protein in cancer cells, while dostarlimab helps the immune system attack the tumor. The goal is to …

This early-phase trial tests a personalized vaccine (PANDA-VAC) made from a patient's own tumor markers, given alongside the immunotherapy drug pembrolizumab. It includes up to 6 people with advanced squamous cell lung cancer or head and neck cancer that cannot be cured. The main…

This phase 3 trial tests whether a combination of two drugs—ramucirumab (which blocks blood vessel growth to tumors) and pembrolizumab (which boosts the immune system)—works better than standard chemotherapy for people with advanced or recurrent non-small cell lung cancer that ha…

This study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…

This phase II trial is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy (platinum and etoposide) can help people with advanced large-cell neuroendocrine lung cancer live longer. About 67 participants who have not had prior systemic treatment wil…

This early-phase study tests whether combining two drugs—sarilumab (Kevzara) and cemiplimab—can safely control non-small cell lung cancer with specific gene changes (EGFR or LKB1/STK11 mutations). About 56 adults with advanced disease will receive the combination. The main goal i…

This phase 2 study tests a new drug (pevonedistat) combined with two standard chemotherapies (carboplatin and paclitaxel) in 27 adults with advanced non-small cell lung cancer that has not responded to immunotherapy. The goal is to see if this combination can shrink or control th…

This study tests whether using a special breathing device (AEROBIKA) after chest surgery can help prevent lung collapse (atelectasis) in people with lung cancer, mediastinal tumors, or mesothelioma. About 72 participants will be randomly assigned to either standard rehab therapy …

This Phase 1 trial tests a new drug called IDE397, alone or with another drug (sacituzumab govitecan), in adults with advanced solid tumors that have a specific genetic change (MTAP deletion) and have stopped responding to standard treatments. The study aims to find safe doses an…

This early-phase trial tests two experimental vaccines (ChAdOx1 and MVA) designed to help the immune system target cancer proteins MAGE-A3 and NY-ESO-1. About 15 adults with advanced non-small cell lung cancer or squamous esophageal cancer will receive the vaccines alongside thei…

This phase 1 trial tests a special type of radiation therapy for lung tumors located very close to the windpipe or esophagus. Using real-time MRI guidance, doctors can adapt the radiation dose daily to target the tumor while sparing nearby organs. Up to 38 patients will receive o…

This study tests a new drug called 9-ING-41, given alone or with chemotherapy, in adults with cancers that have not responded to standard treatments. The goal is to see if the drug is safe and can help control the disease. About 350 people with various advanced cancers, including…

This early-phase trial tests whether adding chest radiation followed by immunotherapy drugs (durvalumab alone or with tremelimumab or olaparib) can help control extensive-stage small cell lung cancer after initial chemotherapy. About 25 adults whose cancer did not worsen after fi…

This phase II trial tests the drug selpercatinib (LOXO-292) in 124 people with stage IV or recurrent non-small cell lung cancer that has a specific genetic change called a RET fusion. The drug works by blocking enzymes that help cancer cells grow. Researchers are measuring how ma…

This study was designed to test two immunotherapy drugs, atezolizumab and tiragolumab, in people with advanced lung cancer that has special immune cell clusters called tertiary lymphoid structures. The trial was withdrawn before enrolling any participants, so no results are avail…

This study tests a new drug called JDQ443, alone or with other treatments, for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the safest dose and see if the drug can shrink tumors. About 344 adults whose cancer has not …

This early-phase trial tests two drugs together—sonidegib and pembrolizumab—in 36 adults with advanced solid tumors that have spread. Sonidegib blocks a growth signal in cancer cells, while pembrolizumab helps the immune system attack the tumor. The main goals are to find the saf…

This program offers capmatinib, an oral drug, to people with advanced non-small cell lung cancer who have no other treatment options and cannot join a clinical trial. It is a managed access (compassionate use) program, not a formal study. The goal is to provide potential benefit …

This study tests a text-message chatbot called 'Penny' that sends reminders and checks in on symptoms for lung cancer patients taking daily targeted therapy pills. 75 patients will either use the chatbot or get usual care, and researchers will measure how well they stick to their…

This early-phase study tests the safety and best dose of a new drug, minnelide, when given with the standard drug osimertinib for people with advanced EGFR-mutated non-small cell lung cancer. The trial enrolls about 8 adults whose cancer has spread or cannot be removed by surgery…

This phase 1/2 trial tests whether adding difluoromethylornithine (DFMO) to the immunotherapy pembrolizumab (Keytruda) is safe and effective for people with advanced non-small cell lung cancer that has a specific genetic change (STK11/LKB1 deficiency). About 45 participants will …

This phase 2 trial tests whether adding the immunotherapy drug durvalumab (Imfinzi) to standard chemotherapy and radiation can help people with limited-stage small cell lung cancer live longer without their cancer growing. About 105 participants will receive either the standard t…

This early-phase study tests a genetically modified herpes virus (RP2) in 36 adults with advanced solid tumors that have not responded to standard treatments. The virus is designed to infect and destroy cancer cells while also stimulating the immune system. Some participants also…

This phase 2 trial tests whether a combination of curcumin (from turmeric) and fish oil can reduce the size of lung nodules in former and current smokers aged 55 and older. Nineteen participants took the supplements or a placebo for 6 months. The study aims to see if the nodules …

This study tests a new drug called HPN328, alone or with other medicines, in people with advanced small-cell lung cancer or neuroendocrine cancers that have a specific marker (DLL3). The main goals are to find the safest dose and understand side effects. About 232 adults will tak…

This study is for people with advanced non-small cell lung cancer who have already tried other treatments. Researchers are testing whether adding an experimental drug called MK-3475 to standard chemotherapy (gemcitabine) is safe and what dose works best. The goal is to control th…

This study tests a combination of three drugs—niraparib, temozolomide, and atezolizumab—in people with advanced solid tumors or extensive-stage small cell lung cancer. The goal is to find the best dose and see if the combination works better than atezolizumab alone as maintenance…

This study looks at whether a blood test (liquid biopsy) can help doctors see how well the drug brigatinib is working in people with a certain type of advanced lung cancer (ALK-positive NSCLC). About 33 patients who have not had chemotherapy before will take brigatinib pills dail…

This study tests a new device that uses microwave energy to destroy small lung tumors. The device is inserted through a bronchoscope, avoiding the need for open surgery. The trial will enroll 35 people with lung nodules that are cancerous or highly suspicious, and who cannot have…

This study tests whether a lung cancer drug called atezolizumab can be safely given as a shot under the skin at home, with doctors monitoring patients through video calls. It involves 5 adults with non-small cell lung cancer. The goal is to see if this home-based approach is prac…

This program offers expanded access to NanoPac, a cancer treatment, for people with advanced pancreatic, prostate, or lung cancer who cannot join ongoing clinical trials. The goal is to provide the drug to those who have no other options. However, the program is no longer availab…

This study tests a new drug, amivantamab, combined with standard targeted therapies (TKIs) in people with advanced non-small cell lung cancer that has specific gene changes (ALK, ROS1, or RET). The goal is to see if this combination can overcome drug resistance and shrink tumors.…

This early-phase trial tests a new approach to treat advanced solid tumors by giving patients a large dose of their own immune cells that are specially selected to attack cancer. The cells are taken from the tumor, multiplied in the lab, and then infused back. Some patients also …

This study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…

This early-stage trial is testing a new drug called KFA115, either by itself or combined with the immunotherapy Keytruda (pembrolizumab), in 126 people with advanced cancers like lung, skin, kidney, and others. The main goal is to check safety and find the best dose. It is not ye…

This phase II study is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy after lung cancer surgery can clear tumor DNA from the blood. The trial enrolls 100 patients with early-stage non-small cell lung cancer who had detectable tumor DNA after s…

This program provides taletrectinib, a targeted cancer pill, to adults with advanced or metastatic ROS1-positive non-small cell lung cancer who cannot join a clinical trial or use approved treatments. Patients must have a ROS1 gene fusion and adequate organ function. The goal is …

This study tests a drug called QBS72S in 21 adults with breast or lung cancer that has spread to the brain. The drug is given once a month through an IV. The main goal is to see if it shrinks brain tumors. The trial is active but not recruiting new participants.

This study tests whether combining two drugs, pembrolizumab and vorinostat, can help control advanced non-small cell lung cancer. About 120 adults with stage IV lung cancer will receive either the combination or pembrolizumab alone. The goal is to see if the combination is safe a…

This early-stage trial tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment combines a specially designed virus (TILT-123) that delivers immune-boosting signals directly into tumors, with the im…

This study tests a drug called AMG 510 in people with advanced lung cancer that has a specific genetic change (KRAS G12C mutation). The drug is designed to block the cancer's growth signal. About 116 participants will receive the treatment to see if it can shrink tumors and slow …

This early-phase trial tests a personalized cell therapy called TBI-1301 for people with advanced solid tumors that express a protein called NY-ESO-1. Patients' own T cells are collected, genetically modified in a lab to better recognize and attack cancer cells, and then infused …

This study looks at whether adding a high-precision type of radiation called SBRT to usual cancer treatments (like hormone therapy or chemo) can delay cancer growth in people with breast, lung, or prostate cancer that has spread to 1 to 5 bones. About 168 adults aged 18-75 with g…

This study tests a new drug called DS-1062a in 100 people with advanced non-small cell lung cancer that has worsened after standard treatments. The drug is given every three weeks and aims to shrink tumors. Researchers will also study how the drug affects the immune system and lo…

This phase 3 trial tests whether the immunotherapy drugs durvalumab (with or without tremelimumab) can help prevent cancer progression in people with limited-stage small cell lung cancer who have completed chemoradiation. About 730 participants will receive either the drug combin…

This study is testing a new way to create tumor-reactive T cells for people with non-small cell lung cancer. Researchers use a nanovaccine made from lung cancer antigens to train T cells to attack the cancer. The goal is to see if these T cells can effectively target tumors in la…

This study tests whether a new drug called QL1706, combined with chemotherapy, works better than another drug (tislelizumab) plus chemo for people with advanced non-small cell lung cancer that lacks the PD-L1 protein. About 606 adults aged 18-75 are taking part. The goal is to se…

This early-phase trial is testing whether adding local treatments like surgery or radiation to the targeted drug brigatinib can help control advanced ALK-positive non-small cell lung cancer. About 35 people who have not yet taken other targeted therapies will receive brigatinib f…

This study tests whether injecting a patient's own blood into the chest tube can stop prolonged air leaks after lung cancer surgery. About 60 adults who still have an air leak three days after surgery will receive the blood patch. Researchers will check if it reduces hospital sta…

This early-stage trial tests a new drug called TPX-0022 in adults with advanced lung, stomach, or other solid tumors that have specific MET gene changes. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. About 95 participants will ta…

This study tests whether adding chest radiation to the immunotherapy drug durvalumab can help people with advanced small cell lung cancer live longer without the disease getting worse. About 46 participants will first receive standard chemotherapy plus durvalumab, then those whos…

This early-stage trial is testing a new drug called HBI-2438 in people with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific genetic change called KRAS G12C. The main goals are to find the safest dose and understand how the drug moves throu…

This study tests a new way to deliver proton radiation for stage II-III non-small cell lung cancer. Instead of standard daily doses over many weeks, patients receive higher doses per session (hypofractionation) over a shorter time, combined with chemotherapy. The goal is to find …

Researchers are testing an experimental imaging agent called MNPR-101-DFO*-89Zr in people with several types of solid tumors, including bladder, breast, lung, and pancreatic cancers. The agent combines an antibody with a radioactive label, which may help PET scans reveal where tu…

This early-phase trial explores whether two experimental PET/CT tracers, 68Ga-FAPI-46 and 68Ga-PSMA-11, can accurately highlight various non-prostate cancers, including breast, lung, and pancreatic tumors. Participants scheduled for surgery will receive the tracers before their s…

This study is testing an artificial intelligence (AI) program called qXR that analyzes chest X-rays to give a lung nodule malignancy score — a number that indicates how likely a lung nodule is to be cancer. Researchers will compare the AI's score to the results of CT scans and ra…

This early-stage study is testing a radioactive imaging agent called [18F]-C-SNAT4 to see how it travels through the body and whether it can help detect lung cancer on PET scans. About 20 healthy volunteers and people with lung cancer will receive the tracer and undergo scans. Th…

This study is testing a new blood test (GuardantLUNAR-2) to see how well it can detect lung cancer in people at high risk. About 12,000 smokers aged 50-80 will give a blood sample before their regular low-dose CT scan. The goal is to find out if the blood test is accurate enough …

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study aims to improve early detection of lung cancer in Asian women who have never smoked, a group at higher risk but not covered by standard screening guidelines. Participants receive up to three low-dose CT scans and a blood test designed to spot early signs of cancer. Res…

This early-phase trial tests a radioactive imaging agent called Technetium-99m HYNIC-FAPI in 15 people with metastatic lung, pancreas, breast, or colorectal cancer. The goal is to see how well it highlights tumors on SPECT/CT scans. Researchers will measure where the agent goes i…

This study compares a robotic bronchoscopy system (Ion) to a manual one (superDimension) for diagnosing lung nodules. About 354 adults with suspicious lung nodules will be randomly assigned to one of the two devices. The main goal is to see which device yields a correct diagnosis…

This study collects blood samples from 872 people with lung nodules to develop artificial intelligence (AI) tools that can help diagnose lung cancer earlier and more accurately. The goal is to combine blood tests with CT scans to improve detection and reduce the need for invasive…

This study is testing a new technology called breathprinting, or electronic nose (e-nose), to see if it can detect early-stage lung cancer. Researchers will collect breath samples from 119 people with suspicious lung nodules before they have a biopsy or surgery. The goal is to se…

This study compares a new technique that combines cone-beam CT scans with a robotic bronchoscope against standard methods for taking lung tissue samples. The goal is to see if the new approach can diagnose lung cancer and other lung diseases more accurately. About 300 adults who …

This Italian study is testing whether heavy smokers can be screened for lung cancer just as effectively with a CT scan every two years instead of every year, and whether a simple blood test can help catch cancers early. Over 7,300 current or former heavy smokers are taking part a…

This study tests whether an artificial intelligence (AI) tool called the Virtual Nodule Clinic can help doctors better manage lung nodules that are not clearly cancerous or benign. The AI analyzes CT scans and patient information to estimate the risk of cancer. The goal is to see…

This study is testing a new blood test (called DELFI) to see how well it can find lung cancer in people at high risk, such as current or former smokers aged 50 and older. Over 11,000 participants provided blood samples, and the test results were compared with standard CT scans an…

This study looks at whether fluid washed from inside a lung tumor can be used to find genetic changes in early-stage lung cancer. About 50 adults with suspected resectable lung cancer will have a special bronchoscopy to collect this fluid. The goal is to see if this method is as …

This study tests a new radioactive tracer called 18F-alphavbeta6-binding-peptide to see if it can safely and clearly show cancers in the breast, colon, lung, or pancreas. About 27 adults with these cancers will get the tracer and have a PET scan. The goal is to find out if this m…

This study compares a new AI system, called COSMO, against 30 board-certified pathologists to see who can more accurately diagnose brain, lung, and kidney cancers. Both the AI and the pathologists will review the same 300 de-identified tissue images. The goal is to see if AI can …

This study looks at a new lab technique called OSNA that may find tiny amounts of cancer in lymph nodes better than current methods. About 130 people with early-stage lung cancer having robotic surgery will take part. Half will have their lymph nodes checked with OSNA, the other …

This study tests a special PET scan that uses a radioactive antibody (64Cu-M5A) to find cancers that produce a protein called CEA. The goal is to see if this scan can detect tumors that standard methods might miss. About 20 adults with CEA-positive cancers (such as breast, colon,…

This study is developing a new blood test called Lung EpiCheck® to find lung cancer early in people at high risk, like heavy smokers. Researchers will collect blood samples and medical information from 5,000 participants to see how accurate the test is. The goal is to create a si…

This study tests whether a lung cancer screening program can work effectively in Germany. Over 12,000 current or former smokers aged 55-79 will be screened using two different risk-based methods to see which finds more cancers early. The goal is to integrate screening into existi…

This study is testing an artificial intelligence software called qXR that automatically analyzes chest X-rays to spot signs of lung cancer. The goal is to see if using AI to prioritize which X-rays need urgent review can speed up the time it takes for patients to get a follow-up …

This study tests whether mobile lung cancer screening units can increase participation among rural adults aged 50 to 80 who smoke or quit within the last 15 years. Researchers will measure how many people get screened and whether their knowledge about lung cancer changes. The goa…

This early-phase trial tests a MUC1 peptide vaccine in 50 current or former smokers at high risk for lung cancer. The vaccine aims to train the immune system to recognize and attack precancerous cells before they become cancer. The study focuses on safety and whether the vaccine …

This study compares two different doses of radiation aimed at the head (prophylactic cranial irradiation) to see which is better at preventing brain metastases in people with small cell lung cancer. Participants had their lung cancer diagnosed within the past year and have alread…

This study was designed to test whether an oral drug called SPI-1005 could prevent hearing loss and ringing in the ears caused by platinum-based chemotherapy. It was planned for adults with advanced lung or head and neck cancer. The study was withdrawn before enrolling any partic…

This study tests whether a combination of low-dose aspirin, a smoking cessation drug called cytisine, and guidance on diet and exercise can reduce chronic inflammation and lower lung cancer risk in heavy smokers aged 55 to 75. The 2000 participants will also receive annual low-do…

This phase 2 trial tests whether metformin, a safe and widely used diabetes drug, can lower the risk of lung cancer in overweight or obese former smokers who are at high risk. About 50 participants will take metformin for 6 months to see if it reduces certain immune cells linked …

This pilot study tests whether a smartphone app called AmDTx can help lung cancer patients manage anxiety before and after surgery. The app includes mindfulness training and a relaxing puzzle game. Only 6 participants are enrolled, and the main goal is to see if people will actua…

Researchers are testing a virtual stress-management program for people who care for a spouse or partner with a solid tumor cancer while also holding a job. The program teaches skills such as paced respiration, relaxation, and coping with work and caregiving demands across eight s…

This study tests a new web-based tool called CONNECT, designed to help caregivers of people with stage II to IV lung cancer find support resources. About 216 caregivers will use the tool and have sessions with a navigator to see if it helps them feel more supported. The goal is t…

This early-stage study tests whether giving a single, very focused dose of radiation after lung cancer surgery is safe and causes fewer side effects than standard weeks-long radiation. It involves 50 adults with non-small cell lung cancer who had surgery but still have cancer cel…

This study tests a nurse-led program designed to help people with advanced lung or gynecologic cancer manage their fears about the future. The program is delivered through video sessions and includes coping strategies. The study will enroll 42 patients to see if the program is pr…

This study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…

This study tests a personalized self-management program to help cancer survivors on immune checkpoint inhibitors better handle side effects and reduce anxiety or depression. About 400 adults with breast, colon, lung, skin, or rectal cancer who recently started immunotherapy will …

This study tests a highly precise radiation system (CT-on-Rails or Trilogy) to treat spine tumors that have spread from other cancers. About 150 participants will receive three radiation sessions over two weeks. Researchers will track pain relief and side effects using patient qu…

This study looks at whether a yoga program can improve physical performance, quality of life, and reduce symptoms for cancer patients undergoing radiation therapy and their partners. About 600 patients with lung, head and neck, or esophageal cancer, along with their partners, wil…

This pilot study tests the drug ruxolitinib in people with advanced non-small cell lung cancer who are experiencing cancer cachexia—unintended weight loss and muscle wasting. The main goal is to check for side effects and see how the drug affects body signals related to appetite …

This study tests whether spiritual care sessions can improve spiritual wellbeing, reduce anxiety and depression, and increase satisfaction with care for people with stage IV lung or gastrointestinal cancer. About 36 adults will be randomly assigned to receive either spiritual car…

This study looks at whether updating radiation treatment plans at set times (adaptive planning) can lower side effects like lung inflammation in people with stage II-IV non-small cell lung cancer. About 34 participants will receive standard radiation and immunotherapy, but their …

This study looks at whether a structured educational program, added to usual care, can help people who have surgery for lung cancer. The goal is to see if it improves how well they accept their disease, their quality of life, and their pain levels. About 160 participants are spli…

This clinical trial tests a 12-week self-management program that combines personalized exercise and nutrition counseling for lung cancer patients experiencing cachexia (unintended weight loss). The study involves 104 participants who will either receive the program or standard ca…

This study looks at whether starting rehabilitation early or later helps reduce cancer-related fatigue in people with lung cancer. About 31 patients with stage II or III lung cancer will take part. The goal is to see if the rehab program is practical and helpful for improving ene…

This study tests whether a 12-week program of online chair-based exercise and health education, combined with a geriatric assessment, is feasible and helpful for adults aged 65+ with certain cancers and their support persons. The program is delivered remotely, and the study will …

This study tests an online program called BREATHE for women with non-small cell lung cancer. The program uses mindfulness, compassion, and emotional processing to help improve social well-being and reduce distress. About 70 women will participate, and the main goal is to see if t…

This study tests whether anamorelin, a drug that stimulates appetite, can help advanced lung cancer patients who have lost their appetite and weight. Researchers will interview 25 patients and compare those taking the drug to those taking a placebo. The goal is to see if the drug…

This study tested a shorter course of high-dose radiation for people with stage IV lung cancer. The goal was to see if giving fewer, larger doses over fewer days could be as safe and effective as the standard longer schedule. 37 participants received radiation every other day for…

This study tests whether a chatbot that texts patients and tracks their phone activity can catch cancer treatment symptoms early. About 70 adults with lung, gastrointestinal, or head and neck cancers will use the chatbot during chemo and radiation. The goal is to see if this appr…

This study tests whether a few counseling sessions can improve quality of life for adults who have just finished lung cancer treatment with the goal of cure. One group gets five sessions focused on coping skills and social support; the other gets one session with referrals. Resea…

This study tests a new robotic surgery technique for stage I lung cancer. Instead of making cuts between the ribs, surgeons place the robot's tools below the ribcage. The goal is to see if this approach is safe and feasible, and if it can reduce pain and hospital stays. The trial…

This phase III trial is testing whether a telehealth self-management program can improve care coordination and quality of life for survivors of non-small cell lung cancer or colorectal cancer. About 403 participants who finished treatment 4 months ago will receive coaching sessio…

This study tests a multimedia self-management program for people with stage I-III lung cancer who are about to have surgery, and their family caregivers. The program includes videos, a handbook, and nurse coaching to help both patients and caregivers feel more prepared. Researche…

This study tests whether a progressive exercise program can reduce chronic pain in veteran lung cancer survivors aged 60-80. Nine participants will do treadmill walking, resistance bands, and balance exercises. The goal is to see if exercise can be a safe alternative to opioids f…

This study tests whether a live, personalized exercise and meditation coaching program, delivered through a digital app, can improve the quality of life for cancer survivors. The trial involves 146 adults who have had breast, lung, prostate, colorectal, or other cancers. Particip…

This study tests two types of nerve blocks to control pain after lung surgery. About 28 adults having lung surgery will get either a Serratus Posterior Superior Intercostal Plane block or an Intercostal Nerve block. The goal is to see which block reduces pain, lowers the need for…

This study looks at whether doing calisthenic exercises (like push-ups and squats) can reduce fatigue and improve attitudes toward exercise in people with lung cancer. Thirty-three patients either exercised with a physiotherapist or followed a booklet at home for 8 weeks. The goa…

This study is testing whether providing medically tailored meals along with nutrition counseling can improve the health and well-being of lung cancer patients who are economically disadvantaged or from minority groups. About 299 patients from four U.S. medical centers will receiv…

This study tests a conversation tool designed to help people with lung cancer understand their options and make decisions that match their values. About 98 patients will use the tool during their care. The goal is to see if it reduces anxiety, regret, and confusion, and improves …

This study tests whether reminder messages can encourage people aged 40-80 who smoke or have smoked to get screened for lung cancer. Researchers will ask about 133 participants how acceptable they find these reminders. The goal is to see if this simple approach could help more pe…

This study looks at how patients with ALK-positive advanced non-small cell lung cancer respond to the drug lorlatinib when used as their first treatment in real-world settings. Researchers will analyze data from 200 patients in a U.S. database to see how long they stay on the dru…

This study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…

This study tests a web-based education tool called HOPE-Genomics that teaches cancer patients about their genetic test results. About 465 adults with breast, colorectal, lung, ovarian, pancreatic, or prostate cancer are taking part. The goal is to see if the tool helps patients r…

This study is watching how patients with EGFR-mutated non-small cell lung cancer do when they receive standard treatment with osimertinib (Tagrisso) alone or with chemotherapy in routine medical practice. About 538 people with advanced lung cancer will be followed to see how long…

This study tests a low-literacy conversation tool designed to help lung cancer patients and their doctors make treatment decisions together. Researchers will enroll 300 patients to see if the tool improves understanding, reduces confusion, and boosts confidence in choices. The fo…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This large study (ALCHEMIST) is screening over 8,000 people with early-stage non-small cell lung cancer to analyze the genes in their tumors. The goal is to identify genetic changes that could help doctors choose the best treatments, such as targeted therapies. Participants provi…

This pilot study aims to see if doctors can consistently measure paclitaxel levels in the blood of cancer patients receiving the drug. The goal is to eventually adjust doses to give enough chemo to fight cancer while reducing the common side effect of nerve damage. The study invo…

This study collects tissue and blood samples from 1,200 adults with known or suspected cancer. The samples are taken during standard surgeries or biopsies, with no extra procedures. Researchers will compare cancerous and normal tissues to identify differences that could lead to n…

This study looks at what happens when older smokers (ages 50-80) who are at high risk for lung cancer switch from regular cigarettes to e-cigarettes. Researchers will track how many cigarettes they smoke and measure health markers like inflammation in their blood. The goal is to …

This study taps into Sweden's national health registers to examine outcomes for thousands of adults who have undergone thoracic surgery, including procedures for lung cancer and pulmonary metastases. By linking detailed patient data, researchers aim to identify factors associated…

This study explores whether a remote, direct-to-patient approach can improve how people with small cell lung cancer (SCLC) are reached and engaged in clinical research. It involves collecting biospecimens and surveying patients about their preferences and needs regarding new ther…

This large study looks at whether regular chest X-rays and health questionnaires can help find lung cancer early and reduce deaths. Over 154,000 people aged 55-74 took part. Researchers compare lung cancer deaths between those who got screened and those who received usual care.

This study looks at whether taking muco-active agents (mucus-thinning drugs like N-acetylcysteine and ambroxol) after a lung cancer diagnosis is linked to better outcomes in people who also have COPD. Researchers will analyze data from a large Korean database, comparing those who…

This study investigates whether bioimpedance analysis, a quick and painless test that measures body water and muscle mass using a weak electrical current, can help predict complications after lung cancer surgery. Researchers will compare these measurements with standard CT scans …

This study looks at two methods for keeping the lungs still during radiation treatment for lung cancer. One method uses a special camera system (SGRT) alone, and the other adds small implanted markers (fiducials) for extra guidance. The goal is to see which approach is more relia…

This study collects extra tissue and a small blood sample from people undergoing standard procedures for lung cancer. Researchers will use these samples to grow miniature versions of the tumors, called organoids, in the lab. The goal is to study how lung cancers grow and change, …

This study compares a new total-body PET/CT scanner (uEXPLORER) with a conventional PET/CT scanner in 180 adults with lung cancer, lymphoma, or melanoma. Each participant gets scanned on both machines to see if the new scanner can produce equally good images in a shorter time. Th…

This study looks at whether a fermented wheat germ supplement can help the immune system fight cancer better when taken with standard immunotherapy drugs. About 100 adults with advanced solid tumors (like lung, colon, or melanoma) will take the supplement alongside their usual tr…

This observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…

This study aims to understand why some people who have never smoked develop lung cancer. Researchers are comparing the genes of never-smokers with lung cancer to those without the disease. The goal is to find genetic differences that might increase risk. This is a research study …

This study aims to find out why some cancer patients develop nerve damage (tingling or numbness in hands and feet) from taxane chemotherapy. Researchers will track over 1,300 people with breast, lung, or ovarian cancer to see how age, gender, and other factors affect their risk. …

This study tests a new way of organizing care for people aged 70 and older who have cancer (breast, lung, colorectal, or prostate) plus at least one other serious health condition. The GERONTE program brings all their doctors and nurses together using a shared digital care plan. …

This study looks at whether educating doctors in small and mid-sized city hospitals can improve how they test and treat patients with advanced non-small cell lung cancer. About 1000 patients will be observed to see if more patients get the right molecular tests and targeted treat…

This study collects tissue samples from 240 adults with lung spots that may turn into cancer. Researchers will analyze these samples to create a detailed map of early changes in the lungs. The goal is to better understand how lung cancer develops and find ways to prevent it.

This study collects blood, urine, and tissue samples from 330 adults with advanced lung or head and neck cancer to improve precision medicine. Researchers will analyze genetic changes in these samples and grow some tumors in mice to compare DNA. The goal is to refine liquid biops…

This study aimed to compare a virtual voice agent with a human agent for teaching cancer patients how to use remote monitoring devices at home. Patients with lung cancer would have been randomly assigned to get instructions from either the virtual agent or a human over the phone.…

This study follows over 1,000 people with newly diagnosed non-small cell lung cancer in community cancer clinics. Researchers want to see how many patients receive key biomarker test results before starting treatment, and what barriers (like tissue issues or insurance problems) c…

This trial tests whether adding care coordination services—like patient navigation and direct communication—can improve how often people get the recommended follow-up after a lung cancer screening. It involves over 6,700 participants across community clinics. The goal is to see i…

This study looks at survival rates for people with cancers like melanoma, breast, colon, and lung cancer using data from Russian cancer registries. It includes 100,000 people of any age. The goal is to understand survival trends to help improve cancer care, not to test a new trea…

This study looks at the genetic makeup of lung cancers found through low-dose CT screening. Researchers want to understand why some cancers grow quickly and others grow slowly. About 526 people who had surgery for screen-detected lung cancer will provide tissue samples for DNA an…

This study collects tissue and blood samples from 1,600 people with various advanced cancers, along with their medical information, over the course of their treatment. Researchers will store these samples and data in a biobank for current and future studies. The goal is to better…

This study follows over 1,800 adults who had early-stage lung cancer treatment to see how often they get CT scans and whether scanning every 6 months helps them live longer than yearly scans. Researchers will also check if scan frequency differs by race, income, or location. The …

This study tests a tool that helps patients with lung cancer or lung metastases work with their doctor to choose the right radiation dose. The tool is designed for tumors very close to the chest wall. The goal is to see if using this tool leads to better shared decision-making an…

This study collects and analyzes lung cancer tissue samples from 500 patients in Asia to find out which genetic changes are most common. The goal is to better understand the disease in the local population. Participants must have a tissue sample available and be healthy enough fo…

This study aims to understand what factors help increase lung cancer screening in people aged 50-80 who smoke or have smoked. Researchers will track how many people get screened and interview staff and patients to learn what works. The goal is to improve screening rates and catch…

This study tracks 126 heavy smokers aged 50 to 74 in France to see how many complete a three-year lung cancer screening program using low-dose CT scans. Researchers also measure how many people quit smoking during the program. The goal is to understand real-world adherence, not t…

This study tests a new computer program that reduces blurring in CT scans used during lung cancer radiation therapy. The goal is to help doctors better locate tumors and track small markers placed in the lungs. About 17 adults with lung cancer who are already scheduled for radiat…

This study looks at lung problems in over 2,000 World Trade Center workers and volunteers. Researchers will review chest CT scans and breathing tests to find signs of airway disease, lung scarring, and cancer. The goal is to better understand how these conditions develop and how …

This study follows 45 uninsured current or former heavy smokers to find early signs of lung cancer. Researchers collect samples like sputum, blood, and urine, and perform CT scans to test new detection methods. The goal is to improve early diagnosis in a group that often misses o…

This study tests a very small camera, called a composite optical fiberscope, to see if it can reach and view lung tumors in the outer parts of the lung. Researchers will use lung tissue removed from 50 patients scheduled for lung cancer surgery. The goal is to see if the camera c…

This study looks at CT scans and other data from 2000 lung cancer patients to build a tool that predicts if the cancer will come back after surgery. The goal is to help doctors decide who needs closer monitoring. It is a retrospective study, meaning it analyzes past information r…

This study looks at whether a CT scan done right after removing a lung tumor can help surgeons decide if they need to remove more tissue. Currently, doctors only know if the cancer is fully removed after the surgery, when a pathologist checks the tissue. By getting immediate feed…

This study looks at circulating tumor cells (CTCs) in the blood of 80 people with advanced lung cancer. Researchers will grow these cells in the lab to test new drugs that target DNA repair. The goal is to learn how to personalize treatment based on each person's tumor cell featu…

This study is tracking over 1,300 people who are having a lung biopsy or lesion localization with the Ion Endoluminal System, a robotic device. The goal is to see how often the device successfully gets a diagnosis and how often complications like a collapsed lung or bleeding occu…

This study tests a new imaging tool called HyperSight that takes clearer, faster pictures during radiation therapy for cancers of the head/neck, breast, lungs, upper GI, or pelvis. The goal is to see if these images are good enough to help doctors plan treatment more precisely, p…

This study compares two robotic platforms, DaVinci Xi and Versius, used in lung surgery to remove tumors or nodules. Researchers want to see if one leads to better recovery, fewer complications, or lower costs. About 150 patients having robotic lung surgery will answer quality-of…

This study tests whether watching a short video can improve understanding of tumor genomic testing in 243 adults with metastatic cancer. Participants watch the video and then answer questions to measure their knowledge. The goal is to see if this simple tool helps patients better…

This study planned to give low-dose chest CT scans to firefighters aged 35 and older to see how many had lung cancer, other cancers, or lung diseases from job-related smoke and chemical exposure. It was withdrawn before any firefighters were enrolled, so no results are available.…

This study examines DNA from over 21,000 cancer patients in New York to find gene changes linked to several cancers, including breast, colon, and lung. Researchers will compare these genes to those from healthy people to spot differences. The goal is to generate ideas for future …

This study looks at whether a new imaging technique (nCLE) can confirm that a biopsy needle is correctly placed in a lung nodule. About 25 adults with suspicious lung nodules will have the extra imaging during their standard biopsy procedure. The goal is to see if this method mat…

This study works with the Choctaw Nation to help more people get screened for lung cancer. Lung cancer is a leading cause of death in American Indian and Alaska Native communities, and screening can catch it early. The program will identify who is eligible, help them schedule and…

This study tests whether combining artificial intelligence with blood biomarkers and CT scan features can better predict lung cancer risk in heavy smokers. Researchers will analyze data from 650 participants to develop a risk model that improves screening accuracy and reduces unn…

This study explores whether a simple breathing test done before surgery can help predict when a patient's oxygen levels might drop dangerously low during lung surgery. Researchers will measure how air moves through the lungs while patients breathe normally, then track oxygen leve…

This study looks at the bacteria living in the gut, lungs, and airways of 40 people with non-small cell lung cancer. Half receive surgery only, and half get chemotherapy before surgery. Researchers collect samples like blood, saliva, stool, and lung tissue to see how these bacter…

This study examines how well immunotherapy works for people with both lung cancer and pulmonary fibrosis (scarred lungs). Researchers will compare 200 patients with both conditions to similar patients without scarring, tracking survival and side effects. They also analyze tumor t…

This early study tests whether using real-time MRI to guide radiation therapy is possible for people with advanced non-small cell lung cancer. The goal is to see if this personalized approach can reduce side effects and better control tumors. About 30 adults with stage III lung c…

This study explores whether a special PET scan using a tracer called FAZA can detect low oxygen (hypoxia) in lung cancer tumors. Hypoxia can affect how tumors grow and respond to treatments like radiation. About 36 adults with stage II or III lung cancer will get one FAZA PET sca…

This study followed 12 people with stage IV non-small cell lung cancer who received both palliative chest radiation and an immunotherapy drug (nivolumab or pembrolizumab). The goal was to track side effects like radiation-related toxicities and patient quality of life. Researcher…

This study collects information from 100 adults with breast, lung, gastrointestinal cancer, or multiple myeloma. Participants fill out weekly online surveys about their symptoms and treatment experiences for at least 12 weeks. The goal is to learn how symptoms change over time an…

This study tests a new payment model for cancer care in Hawaii. Instead of paying for each service separately, doctors get a single payment for an episode of care, with bonuses for meeting quality goals. The study includes 7 oncologists and looks at how this affects care quality,…

This study looks at whether a 12-week virtual exercise program with group counseling can reduce inflammation and improve gut bacteria in smokers at high risk for lung cancer. About 65 participants aged 50-77 who smoke or used to smoke will take part. The goal is to see if this ap…

This study follows 160 lung cancer patients to see if their muscle mass, strength, and function are linked to how well they tolerate treatment and their overall survival. Researchers will also explore why some patients struggle to complete their therapy. The goal is to find ways …

This study watches 25 people with breast or lung cancer who are getting immune checkpoint inhibitor therapy. Researchers use heart scans and blood tests to see if the treatment harms the heart's tiny blood vessels. No new drugs are given; the goal is to learn how to better protec…

This study looks at whether special 4DCT scans can help doctors avoid damaging healthy lung tissue during radiation therapy for lung cancer. Researchers will compare standard radiation plans with ones that use lung function maps to spare well-working lung areas. The study uses ex…

This study looks at conversations between lung cancer patients and their healthcare providers. Researchers want to learn how these talks affect patient well-being and satisfaction. About 294 patients will take part, sharing their experiences through interviews and questionnaires.…

This study tests a new technology that adjusts the radiation beam in real time to follow lung tumors as they move with breathing. About 20 adults with early-stage lung cancer or limited lung metastases will receive standard radiotherapy with this tracking system. The main goal is…

This study will use advanced heart scans (coronary CT angiography) on 4,000 people with rheumatoid arthritis aged 50-75. The goal is to better understand why people with this condition have higher risks of heart attacks, strokes, and lung problems. Researchers will track particip…

This study tests a new X-ray technique to track lung tumors during radiation without needing implanted markers. Five adults with early-stage lung cancer will be observed to see if the markerless method matches the standard marker-based tracking within 3 millimeters. If it works, …

This study looks at the best way to collect tissue samples from lung cancer patients using a thin tube passed through the mouth (endobronchial ultrasound). It compares taking 2 versus 3 samples from each lymph node to see if fewer samples still provide enough material for genetic…

This study looks at whether having low muscle mass (sarcopenia) before lung cancer surgery affects how well patients recover. Researchers will follow 400 older adults having lung cancer surgery to see if sarcopenia is linked to survival and other outcomes. The goal is to find out…

This study tests two simple approaches to help people stick with annual lung cancer screening: automated reminders for doctors and patients, plus an educational video. About 1,837 adults aged 50-78 who already had a negative scan are taking part at Kaiser Permanente Washington. T…

This research study collects blood, tumor tissue, and other body fluids from 1,000 adults with lung cancer, thymus cancer, or mesothelioma. The goal is to analyze these samples to find biological markers that could predict how the disease will progress or which treatments might w…

This study tests whether a new method called the Engaged Approach to Lung Cancer Screening (EA-LCS) is practical and acceptable for use in different lung cancer screening programs across Colorado and the US. Researchers will ask staff at up to 8 screening sites to try the approac…

Researchers at Moffitt Cancer Center are studying whether tiny plastic particles, called microplastics, are present in the lungs of people with and without lung cancer. They will collect fluid from the lungs during a standard bronchoscopy procedure and analyze it for microplastic…

This study looks back at medical records of 10,000 people with non-small cell lung cancer who received immunotherapy before surgery. Researchers want to find out which follow-up treatments after surgery help patients live longer and reduce the chance of cancer coming back. The go…

This study looks at whether certain inherited gene changes (EGFR mutations) increase the risk of lung cancer, especially in people who never smoked. Researchers collect saliva from cancer patients with a specific tumor mutation (T790M) to find these inherited changes. They also o…

This study tests whether a remote monitoring system—including a smartphone app, a Fitbit, and a smart pill cap—can effectively track symptoms and side effects in 30 lung cancer patients taking oral targeted therapy. Participants will use the system for up to 24 weeks, and the goa…

This early-stage study tests whether a dye called indocyanine green, injected near a lung tumor during surgery, can help surgeons see and remove the first lymph node that drains from the cancer. The goal is to improve detection of cancer spread and guide more precise treatment. T…

This study looks at 80 lung cancer patients with complex conditions, like rare tumor types or previous radiation, to see how well radiotherapy works and what side effects occur. The goal is to gather information to help doctors make better treatment decisions for future patients.…

This study tracks 221 people with stage II or III lung cancer to see how chemoradiation therapy affects their heart health. Participants undergo heart scans, blood tests, and quality-of-life surveys before, during, and for at least two years after treatment. The goal is to better…

This study planned to see if an artificial intelligence (AI) program called qXR-LN could help radiologists find more lung nodules and cancers on chest X-rays. Researchers would compare how often nodules were detected before and after the AI was put into use. The study was withdra…